VRTX vs VTVT
VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain. VTVT: A late-stage biopharmaceutical company developing cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials for type 1 diabetes, with FDA Breakthrough Therapy designation.
Side-by-side fundamentals
| Metric | VRTX | VTVT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $472.57 | $31.67 | |
| Market cap as of 2026-07-23 | $121.4B | $124M | |
| P/E as of 2026-07-23 | 27.98 | 55.08 | VRTX lower |
| PEG as of 2026-07-23 | 2.31 | n/a | |
| Net margin as of 2026-07-23 | +35.5% | +65.5% | VTVT higher |
| Gross margin as of 2026-07-23 | +86.2% | n/a | |
| Operating margin as of 2026-07-23 | +38.3% | +63.1% | VTVT higher |
| ROE as of 2026-07-23 | +23.9% | +4.0% | VRTX higher |
| ROA as of 2026-07-23 | +17.2% | +2.9% | VRTX higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.00 | VTVT lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.1% | +216600.0% | VTVT higher |
| Revenue CAGR (3y) SEC XBRL | +10.4% | n/a | |
| Beta as of 2026-07-23 | 0.30 | 0.29 | |
| 1-year return as of 2026-07-22 close | +0.5% | -69.6% | VRTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.